Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central anxious program, conolidine modulates alternate molecular targets. A Science Advancements study discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By... https://brooksxfgig.tribunablog.com/conolidin-to-replace-traditional-painkillers-options-52562977